PUMA
Istituto di Fisiologia Clinica     
Andreassi M. G., Botto N., Maffei S. Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening. In: Clinical Chemistry and Laboratory Medicine, vol. 44 (5) pp. 514 - 521. Walter de Gruyter, 2006.
 
 
Abstract
(English)
Venous thromboembolism is a well-known complication of oral contraception and hormonal replacement therapy. Inherited thrombophilia is viewed as an important determinant in modulating the effects of estrogens on thrombotic risk. An increasing number of kits for thrombophilic mutations [factor V Leiden, G20210A prothrombin and methylenetetrahydrofolate reductase (MTHFR) C677T genes] are becoming commercially available, and screening for inherited thrombotic risk is among the most requested genetic tests in molecular diagnostic laboratories. However, the question of routine genetic screening for thrombophilia before prescribing hormones is still a matter of debate. The purpose of this article is to discuss the usefulness and practical applications of thrombotic genetic testing to identify which women should be tested to improve both the safety and efficacy of individualized estrogen therapy.
URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16681418&query_hl=1&itool=pubmed_docsum
Subject Genetic testing
Hormonal replacement therapy
Inherited thrombophilia
Oral contraception
Thrombotic risk


Icona documento 1) Download Document PDF


Icona documento Open access Icona documento Restricted Icona documento Private

 


Per ulteriori informazioni, contattare: Librarian http://puma.isti.cnr.it

Valid HTML 4.0 Transitional